Cargando…
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
BACKGROUND: Human papilloma virus type 16 (HPV16)-induced gynecological cancers, in particular cervical cancers, are found in many women worldwide. The HPV16 encoded oncoproteins E6 and E7 are tumor-specific targets for the adaptive immune system permitting the development of an HPV16-synthetic long...
Autores principales: | van Poelgeest, Mariette I E, Welters, Marij J P, van Esch, Edith M G, Stynenbosch, Linda F M, Kerpershoek, Gijs, van Persijn van Meerten, Els L, van den Hende, Muriel, Löwik, Margriet J G, Berends-van der Meer, Dorien M A, Fathers, Lorraine M, Valentijn, A Rob P M, Oostendorp, Jaap, Fleuren, Gert Jan, Melief, Cornelis J M, Kenter, Gemma G, van der Burg, Sjoerd H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623745/ https://www.ncbi.nlm.nih.gov/pubmed/23557172 http://dx.doi.org/10.1186/1479-5876-11-88 |
Ejemplares similares
-
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions
por: de Vos van Steenwijk, Peggy J., et al.
Publicado: (2012) -
Synergy of therapeutic vaccination against HPV16 oncogenic proteins and standard chemotherapeutics
por: Melief, Cornelis J, et al.
Publicado: (2014) -
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions
por: Speetjens, Frank M, et al.
Publicado: (2022) -
Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination
por: Abdulrahman, Ziena, et al.
Publicado: (2020) -
Interferon‐γ and IL‐5 associated cell‐mediated immune responses to HPV16 E2 and E6 distinguish between persistent oral HPV16 infections and noninfected mucosa
por: Paaso, Anna, et al.
Publicado: (2021)